TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12930169

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (2 g per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11139109

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10^6 KIU pre-CPB, 2 x 10^6 KIU in prime, 500,000 KIU/hr during CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9110123

Group type: EXPERIMENTAL
Intervention: HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrates (bezafibrate, fenofibrate, gemfibrozil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 17.3 mg/day or 20 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 0
Study: 1283370

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3828570

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30178240

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 30482480

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone palmitate once-monthly
Number of subjects: 0
Study: 27529625

Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks)
Number of subjects: 25
Study: 25384814

Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR) assessment completed by staff
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: My Own Health Report (MOHR) assessment completed by patients
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Implementation of MOHR
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Overall adoption of MOHR by practices
Number of subjects: 3591

Group type: EXPERIMENTAL
Intervention: Sustainability of MOHR assessment
Number of subjects: 3591
Study: 23165413

Group type: EXPERIMENTAL
Intervention: Online application of SCIP-S
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional application of SCIP-S
Number of subjects: 30
Study: 20198649

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17650131

Group type: EXPERIMENTAL
Intervention: Maternal training in elaborative reminiscing
Number of subjects: 115
Study: 15162916

Group type: EXPERIMENTAL
Intervention: Cardixin (0.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lanoxin (0.25 mg)
Number of subjects: 12
Study: 11641292

Group type: EXPERIMENTAL
Intervention: Pet ownership with lisinopril (20 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lisinopril (20 mg/d) only
Number of subjects: 48
Study: 9842768

Group type: EXPERIMENTAL
Intervention: Fragile-X syndrome group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (mainstream schoolchildren)
Number of subjects: 0
Study: 7978396

Group type: EXPERIMENTAL
Intervention: Active warming (Group I)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Passive cooling (Group II)
Number of subjects: 22
Study: 2692407

Group type: EXPERIMENTAL
Intervention: 3‐day treatment of daily 2‐h infusions of 0.5 mg/kg in 250 ml of saline (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single 24‐h infusions of 1.5 mg/kg (group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Single 24‐h infusions of 0.5 mg/kg in 1 liter of saline (group C)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Group C (0.5 mg/kg in 1 liter of saline)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 30454019

Group type: EXPERIMENTAL
Intervention: Flexible family visitation model (FFVM) - 12 consecutive ICU visiting hours per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Restrictive family visitation model (RFVM) - < 4.5 ICU visiting hours per day
Number of subjects: 100
Study: 28939582

Group type: EXPERIMENTAL
Intervention: Intervention messages delivered via mobile app
Number of subjects: 570

Group type: COMPARATOR
Intervention: Control messages about trial participation
Number of subjects: 570
Study: 25448244

Group type: EXPERIMENTAL
Intervention: Task-oriented motor learning intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 40
Study: 22784703

Group type: EXPERIMENTAL
Intervention: Stay Cool Kids intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 264
Study: 22027717

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (SeQuent Please, B-Braun)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (Xience V/Xience Prime, Abbott Vascular)
Number of subjects: 0
Study: 18438223

Group type: EXPERIMENTAL
Intervention: Complex training program (2 sessions per week for 10 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (CG; n = 10)
Number of subjects: 25
Study: 16536810

Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 89

Group type: COMPARATOR
Intervention: Curettage and electrodesiccation
Number of subjects: 89
Study: 15055043

Group type: EXPERIMENTAL
Intervention: Loco-Regional Anaesthesia (LRA)
Number of subjects: 72

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 72
Study: 16192522

Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg
Number of subjects: 215

Group type: COMPARATOR
Intervention: placebo (control)
Number of subjects: 215
Study: 10492856

Group type: EXPERIMENTAL
Intervention: Combined continuation ECT and flupenthixol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuation ECT alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Flupenthixol alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Maintenance ECT combined with neuroleptic medication (Phase III study)
Number of subjects: 51
Study: 8567331

Group type: EXPERIMENTAL
Intervention: Combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 1, 30 cases)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of conventional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 2, 33 cases)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination of systemic chemotherapy and split-course radiotherapy (Group 3, 33 cases)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional radiotherapy only (Group 4, 30 cases)
Number of subjects: 126
Study: 1843989

Group type: EXPERIMENTAL
Intervention: Combination of chloral hydrate (CH) and hydroxyzine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral examination
Number of subjects: 15
Study: 7043008

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times daily for seven days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 28291891

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation followed by monitored home-based program
Number of subjects: 165

Group type: COMPARATOR
Intervention: Home-based rehabilitation alone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 165

Group type: COMPARATOR
Intervention: Home-based rehabilitation
Number of subjects: 165
Study: 24628110

Group type: EXPERIMENTAL
Intervention: Cognitive arousal (trauma video)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (pleasant video)
Number of subjects: 34
Study: 24491072

Group type: EXPERIMENTAL
Intervention: SB in-person BASICS
Number of subjects: 783

Group type: COMPARATOR
Intervention: SB web BASICS (with and without friends)
Number of subjects: 783

Group type: COMPARATOR
Intervention: General BASICS
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: SB in-person BASICS with friend
Number of subjects: 783

Group type: COMPARATOR
Intervention: SB web BASICS with friend
Number of subjects: 783

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 783
Study: 23534280

Group type: EXPERIMENTAL
Intervention: Enterosorbent White Coal (aerosil)
Number of subjects: 0
Study: 19059524

Group type: EXPERIMENTAL
Intervention: Modified transdermal HRT (micronized 17beta-estradiol and progesterone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Orally given HST (Cyclo-Menorette)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 75
Study: 17302660

Group type: EXPERIMENTAL
Intervention: 800 IU vitamin D
Number of subjects: 124

Group type: COMPARATOR
Intervention: 200 IU vitamin D
Number of subjects: 124

Group type: COMPARATOR
Intervention: 400 IU vitamin D
Number of subjects: 124

Group type: COMPARATOR
Intervention: 600 IU vitamin D
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 15371986

Group type: EXPERIMENTAL
Intervention: Rifampin (hepatic/intestinal CYP3A induction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Troleandomycin (hepatic/intestinal CYP3A inhibition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (selective intestinal CYP3A inhibition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nothing (control)
Number of subjects: 0
Study: 11606958

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal endoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lateral cephalometric radiography
Number of subjects: 30
Study: 9682184

Group type: EXPERIMENTAL
Intervention: Behavioural advice for the child's sleep problem
Number of subjects: 30

Group type: COMPARATOR
Intervention: No behavioural advice (Control)
Number of subjects: 30
Study: 7991070

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH, 500 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GH-releasing hormone (GHRH, 100 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP, 100 micrograms)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Peptide histidine methionine (PHM, 100 micrograms)
Number of subjects: 28
Study: 2663151

Group type: COMPARATOR
Intervention: Amitriptyline (AMI) 75 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Mianserin (MIA) 60 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Trazodone (TRA) 150 mg p.o.t.i.d. for 5 weeks
Number of subjects: 106
Study: 30048227

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (Control group, n = 12)
Number of subjects: 24
Study: 30081694

Group type: EXPERIMENTAL
Intervention: Ablative fractional CO2 laser followed by topical compound betamethasone solution plus NB‐UVB (5 sessions, one month apart)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Topical betamethasone cream once a day plus NB‐UVB (3 times per week)
Number of subjects: 289
Study: 28779371

Group type: EXPERIMENTAL
Intervention: Voglibose (0.6 mg/day)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: No drugs (control)
Number of subjects: 3000
Study: 26075646

Group type: EXPERIMENTAL
Intervention: Running absorbable suture placement at the staple line
Number of subjects: 146

Group type: COMPARATOR
Intervention: No suture placement
Number of subjects: 146
Study: 23258816

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6492

Group type: COMPARATOR
Intervention: Ranolazine vs Placebo
Number of subjects: 6492
Study: 21329525

Group type: EXPERIMENTAL
Intervention: 16-weeks exercise program with focus on fall prevention delivered by specifically trained local physiotherapists
Number of subjects: 382

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study: 20921349

Group type: EXPERIMENTAL
Intervention: HIV/STD risk-reduction intervention
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Health promotion control intervention
Number of subjects: 1057
Study: 17400624

Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 29

Group type: COMPARATOR
Intervention: Declining participation in clinical trials
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Knowledge and feelings towards trials
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Trust in pharmaceutical industry and doctors
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Public control measures
Number of subjects: 29
Study: 15752392

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fentanyl (1 microg kg(‐1) intravenous before skin incision)
Number of subjects: 48
Study: 12034600

Group type: EXPERIMENTAL
Intervention: 60 mL of a nonionic contrast agent (250 mg I/mL) injected at a 3 mL/sec flow rate
Number of subjects: 200

Group type: COMPARATOR
Intervention: 80 mL of the same contrast agent injected at a 4 mL/sec flow rate
Number of subjects: 200
Study: 10438694

Group type: EXPERIMENTAL
Intervention: Psychosocial or clinical management (CM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive CM
Number of subjects: 0
Study: 7495046

Group type: EXPERIMENTAL
Intervention: Bicycle training with individual choice of physical loading (group 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bicycle training with preset intensity (50% of individual exercise tolerance) (group 1)
Number of subjects: 107
Study: 2312777

Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: metoprolol Durules 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7191754

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 10
Study: 30776899

Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans (6 g/day)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo control (maltodextrin)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Prebiotic inulin‐type fructans during antibiotic treatment
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation
Number of subjects: 258
Study: 28813425

Group type: EXPERIMENTAL
Intervention: Dynamic education module
Number of subjects: 933

Group type: COMPARATOR
Intervention: Static education module
Number of subjects: 933
Study: 25530426

Group type: EXPERIMENTAL
Intervention: Combination therapy (varenicline + bupropion SR)
Number of subjects: 505
Study: 23657861

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium tack
Number of subjects: 40
Study: 21948500

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) during HBOT
Number of subjects: 6

Group type: COMPARATOR
Intervention: HBOT without NPWT
Number of subjects: 6
Study: 19807887

Group type: EXPERIMENTAL
Intervention: 0.1 ml x kg(‐1) of 1% lidocaine with epinephrine 0.5 microg x kg(‐1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline intravenously
Number of subjects: 68
Study: 16780671

Group type: EXPERIMENTAL
Intervention: Akatinol memantine 5 mg/d in first week, 10 mg/d in second week, 15 mg/d in third week and 20 mg/d from fourth to sixteenth week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Donepezil 5 mg/d
Number of subjects: 100
Study: 15146342

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 142

Group type: COMPARATOR
Intervention: low-dose haloperidol
Number of subjects: 142
Study: 12146184

Group type: EXPERIMENTAL
Intervention: VACUTEX capillary action wound dressing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard protocol for the treatment of sloughy and necrotic wounds
Number of subjects: 35
Study: 8985633

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 0.1% solution
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 8260856

Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (10(‐5) M in 2 ml)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Prednisolone (25 mg in 2 ml)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 156
Study: 2888651

Group type: EXPERIMENTAL
Intervention: Adenosine (1/3, 2/3, and full maximum tolerable dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol (10 mg to males, 8 mg to females)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31539289

Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Accessorized prefilled syringe (APFS)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Thigh administration
Number of subjects: 180

Group type: COMPARATOR
Intervention: APFS vs. AI
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both devices (AI and APFS)
Number of subjects: 180
Study: 30418198

Group type: EXPERIMENTAL
Intervention: Copenhagen adduction (CA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sliding hip (SH)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matched control (C)
Number of subjects: 42
Study: 28875250

Group type: EXPERIMENTAL
Intervention: Iris registration FEMTOLASIK
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-iris registration FEMTOLASIK
Number of subjects: 59
Study: 26689403

Group type: EXPERIMENTAL
Intervention: Newborn screening (NBS)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Late onset (LO) patients
Number of subjects: 567

Group type: COMPARATOR
Intervention: Various metabolic treatment strategies
Number of subjects: 567
Study: 22716232

Group type: EXPERIMENTAL
Intervention: Single-legged heel-rise test
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ability to perform a heel-rise
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 81
Study: 22356470

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 500U
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 19742382

Group type: EXPERIMENTAL
Intervention: Choice group (participants chose their preferred treatment)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: No choice group (participants were assigned to their preferred treatment but believed they couldn't choose)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wait-list control group (participants received no treatment until the end of the study)
Number of subjects: 73
Study: 18533842

Group type: EXPERIMENTAL
Intervention: Children (<10 years)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Adults (21-50 years)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Patients (>50 years)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: All ages
Number of subjects: 1050
Study: 15321434

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.15 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12904147

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for anticoagulant-related bleeding
Number of subjects: 0
Study: 9822268

Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 24
Study: 7916025

Group type: EXPERIMENTAL
Intervention: 0.1% metipranolol HCl + 2% pilocarpine HCl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.1% metipranolol HCl + 4% pilocarpine HCl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol HCl + 2% pilocarpine HCl
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.3% metipranolol HCl + 4% pilocarpine HCl
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.1% metipranolol HCl
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.3% metipranolol HCl
Number of subjects: 19

Group type: COMPARATOR
Intervention: 2% pilocarpine HCl
Number of subjects: 19

Group type: COMPARATOR
Intervention: 4% pilocarpine HCl
Number of subjects: 19
Study: 2473952

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 31

Group type: COMPARATOR
Intervention: Inosine pranobex
Number of subjects: 31
Study: 702219

Group type: EXPERIMENTAL
Intervention: HDFP treatment (step-wise pharmacologic regimen)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control group (referred to their physicians for treatment)
Number of subjects: 513
Study: 31645614

Group type: EXPERIMENTAL
Intervention: Weighted gene co-expression network analysis (WGCNA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compounds affecting anti-inflammatory pathways and drugs targeting coagulation pathways
Number of subjects: 0
Study: 27251666

Group type: EXPERIMENTAL
Intervention: Liberal blood transfusion strategy (Hb levels ≥11.3 g/dL)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Restrictive blood transfusion strategy (Hb levels ≥9.7 g/dL)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Liberal blood transfusion strategy (LB)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Development of postoperative delirium (POD)
Number of subjects: 179
Study: 25869371

Group type: EXPERIMENTAL
Intervention: Support‐Transform‐Achieve‐Results Intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual Practice group
Number of subjects: 93
Study: 22628369

Group type: EXPERIMENTAL
Intervention: Group condition (immediate intervention)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual condition (delayed intervention)
Number of subjects: 80
Study: 21654270

Group type: EXPERIMENTAL
Intervention: 40 mg/d febuxostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg/d febuxostat
Number of subjects: 0
Study: 19344008

Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support System (CDSS) intervention with reminders every 4 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adequately treated with lipid-lowering drugs
Number of subjects: 56